OJN  Vol.4 No.4 , April 2014
Oxaliplatin Induced Neurotoxicity among Patients with Colorectal Cancer: Documentation in Medical Records—A Pilot Study
Abstract: Patients with colorectal cancer (CRC) can have chemotherapy with oxaliplatin postoperatively. Oxaliplatin can cause acute and chronic neurotoxicity. It is important to be aware of neurotoxic side effects so they can be documented and action taken at an early stage. The study aimed to identify and explore neurotoxic side effects documented in the medical records of patients with colorectal cancer treated with oxaliplatin-based adjuvant chemotherapy. Data in this study were medical records; presenting documentation about patients treated at the University Hospital in the south of Sweden between 2009 and 2010. A summative content analysis approach was used to explore the neurotoxic side effects. Identification and quantification of the content of medical records were carried out by using a study-specific protocol. “Cold sensitivity” and “tingling in the hands” were the most frequently documented neurotoxicity-related terms in the medical records. This identification was followed by interpretation. Three categories were identified in the interpretive part of the study: acute, chronic, and degree of neurotoxicity. The results show the importance of awareness of neurotoxic side effects so that they can be documented and action taken at an early stage. The documentation could be more reliable if patient-reported structured measurements were used, combined with free descriptions in the medical records. Being able to follow the progression of the symptoms during and after treatment would improve patient’s safety and also quality of life. The protocol that we developed and used in this review of medical records may be helpful to structure the documentation in the electronic system for documentation of neurotoxicity side effects.
Cite this paper: Drott, J. , Starkhammar, H. , Börjeson, S. and Berterö, C. (2014) Oxaliplatin Induced Neurotoxicity among Patients with Colorectal Cancer: Documentation in Medical Records—A Pilot Study. Open Journal of Nursing, 4, 265-274. doi: 10.4236/ojn.2014.44031.

[1]   Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E. and Forman, D. (2011) Global Cancer Statistics. CA: A Cancer Journal for Clinicians, 61, 69-90.

[2]   Oncology Center (2008) National Health Careprogram Forcolorectal Cancer.

[3]   Grothey, A. (2006) Recognizing and Managing Toxicities of Molecular Targeted Therapies for Colorectal Cancer. Oncology, 20, 21-28.

[4]   Wolfe, S., Barton, D., Kottschade, L., Grothey, A. and Loprinzi, C. (2008) Chemotherapy-Induced Peripheral Neuropathy: Prevention and Treatment Strategies. European Journal of Cancer, 44, 1507-1515.

[5]   Provencher, S., Oeheler, C., Lavertu, S., Jolicoeur, M., Fortin, B. and Donath, D. (2010) Quality of Life and Tumor Control after Short Split-Course Chemoradiation for Anal Canal Carcinoma. Radiation Oncology, 41, 1-8.

[6]   Benson III, A.B., Guillem, J.G. and Minsky, B.D. (2011) Have the Changes in Treatment of Rectal Cancer Made a Significant Difference to Our Patients? Oncology, 25, 1323-1329.

[7]   Tofthagen, C., McAllister, R.D. and McMillan, S.C. (2011) Peripheral Neuropathy in Patients with Colorectal Cancer Receiving Oxaliplatin. Clinical Journal of Oncology Nursing, 15, 182-188.

[8]   Bakitas, M. (2007) Background Noise. The Experience of Chemotherapy-Induced Peripheral Neuropathy. Nursing Research, 56, 323-331.

[9]   Grenon, N. and Chan, J. (2009) Managing Toxicities Associated with Colorectal Cancer Chemotherapy and Target Therapy: A New Guide for Nurses. Clinical Journal of Oncology Nursing, 3, 285-296.

[10]   Mols, F., Beijers, T., Lemmens, V., van den Hurk, C.J., Vreugdenhil, G. and van de Poll-Franse, L.V. (2013) Chemotherapy-Induced Neuropathy and Its Association with Quality of Life among 2-to 11-Year Colorectal Cancer Survivors: Results from the Population-Based PROFILES Registry. Journal of Clinical Oncology, 20, 2699-2707.

[11]   Pietrangeli, A., Leandr, M., Terzoli, E., Jandolo, B. and Garufi, C. (2006) Persistence of High-Dose Oxaliplatin-Induced Neuropathy at Long-Term Follow-Up. European Neurology, 56, 13-16.

[12]   Tofthagen, C., Donovan, K.A., Morgan, M.A., Shibata, D. and Yeh, Y. (2013) Oxaliplatin-Induced Peripheral Neuropathy’s Effects on Health-Related Quality of Life of Colorectal Cancer Survivors. Supportive Care in Cancer, 21, 3307-3313.

[13]   Verstappen, C., Heimans, J., Hoekman, K. and Postma, T.J. (2003) Neurotoxic Complications of Chemotherapy in Patients with Cancer-Clinical Signs and Optimal Management. Drugs, 63, 1549-1563.

[14]   Beak, K.K., Lee, J., Park, S.H., Park, J.O., Park, Y.S., Lim, H.Y., Kang, W.K., Cho, Y.B., Yun, S.H., Kim, H.C., Lee, W.Y. and Chun, H.K. (2010) Oxaliplatin-Induced Chronic Peripheral Neurotoxicity: A Prospective Analysis in Patients with Colorectal Cancer. Cancer Treatment and Research, 42, 185-190.

[15]   De Gramont, A., Buyse, M., Abrahantes, J.C., Burzykowski, T., Quinaux, E., Cervantes, A., Figer, A., Lledo, G., Flesch, M., Mineur, L., Carola, E., Etienne, P.L., Rivera, F., Chirivella, I., Perez-Staub, N., Louvet, C., André, T., Tabah-Fisch, I. and Tournigand, C. (2007) Reintroduction of Oxaliplatin Is Associated with Improved Survival in Advanced Colorectal Cancer. Journal of Clinical Oncology, 25, 3224-3229.

[16]   Kemeny, N., Garay, C.A., Gurtler, J., Hochster, H., Kennedy, P., Benson, A., Brandt, D.S., Polikoff, J., Wertheim, M., Shumaker, G., Hallman, D., Burger, B. and Gupta, S. (2004) Randomized Multicenter Phase II Trial of Bolus plus Infusional Fluorouracil/Leucovorin Compared with Fluorouracil/Leucovorin plus Oxaliplatin as Third-Line Treatment of Patients with Advanced Colorectal Cancer. Journal of Clinical Oncology, 22, 4753-4761.

[17]   Maindrault-Goebel, F., Tournigand, C., Andre, T., Carola, E., Mabro, M., Artru, P., Louvet, C. and de Gramont, A. (2004) Oxaliplatin Reintroduction in Patients Previously Treated with Leucovorin, Fluorouracil and Oxaliplatin for Metastatic Colorectal Cancer. Annals of Oncology, 15, 1210-1214.

[18]   Velasco, R., Bruna, J., Briani, C., Argyriou, A., Cavaletti, G., Alberti, P., Frigeni, B., Cacciavillani, M., Lonardi, S., Cortinovis, D., Cazzaniga, M., Santos, C. and Kalofonos, H. (2013) Early Predictors of Oxaliplatin-Induced Cumulative Neuropathy in Colorectal Cancer Patients. Journal of Neurology, Neurosurgery, and Psychiatry, 85, 392-398.

[19]   Wilkes, G.M. (2007) Maximising Treatment Benefit for Colorectal Cancer Patients through Evidence-Based Toxicity Management Strategies: Focus on Skin Toxicity and Peripheral Neuropathy. Colorectal Cancer Nursing, 1, 4-6.

[20]   Grothey, A. (2010) Reintroduction of Oxaliplatin: A Viable Approach to the Long-Term Management of Metastatic Colorectal Cancer. Oncology, 79, 389-399.

[21]   Hoff, P.M., Saad, E.D., Costa, F., Coutinho, A.K., Caponero, R., Prolla, G. and Gansl, R.C. (2012) Literature Review and Practical Aspects on the Management of Oxaliplatin-Associated Toxicity. Clinical Colorectal Cancer, 11, 93-100.

[22]   Cavaletti, G., Cornblath, D.R., Merkies, I.S., Postma, T.J., Rossi, E., Frigeni, B., Alberti, P., Bruna, J., Velasco, R., Argyriou, A.A., Kalofonos, H.P., Psimaras, D., Ricard, D., Pace, A., Galiè, E., Briani, C., Dalla Torre, C., Faber, C.G., Lalisang, R.I., Boogerd, W., Brandsma, D., Koeppen, S., Hense, J., Storey, D., Kerrigan, S., Schenone, A., Fabbri, S. and Valsecchi, M.G. (2013) The Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Standardization Study: From Consensus to the First Validity and Reliability Findings. Annals of Oncology, 24, 454-462.

[23]   Bennett, K., Park, S., Lin, C., Friedlander, M., Kiernan, M.C. and Goldstein, D. (2012) Impact of Oxaliplatin-Induced Neuropathy: A Patient Perspective. Supportive Care in Cancer, 20, 2959-2967.

[24]   Hsieh, H.F. and Shannon, S.E. (2005) Three Approaches to Qualitative Content Analysis. Qualitative Health Research, 15, 1277-1288.

[25]   Kondracki, N.L., Wellman, N.S. and Amundson, D.R. (2002) Content Analysis: Review of Methods and Their Applications in Nutrition Education. Journal of Nutrition Education and Behavior, 34, 224-230.

[26]   Leonard, G.D., Wright, M.A., Quinn, M.G., Fioravanti, S., Harold, N., Schuler, B., Thomas, R.R. and Grem, J.L. (2005) Survey of Oxaliplatin-Associated Neurotoxicity Using an Interview-Based Questionnaire in Patients with Metastatic Colorectal Cancer. BMC Cancer, 5, 116-125.

[27]   Haller, D.G., Catalano, P.J. and Macdonald, J.S. (2005) Phase III Study of Fluorouracil, Leucovorin, and Levamisole in High Risk Stage II and III Colon Cancer: Final Report of Intergroup 0089. Journal of Clinical Oncology, 22, 3408-3419.

[28]   André, T., Boni, C., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Bonetti, A., Clingan, P., Bridgewater, J., Rivera, F. and de Gramont, A. (2009) Improved Overall Survival with Oxaliplatin, Fluorouracil and Leucovorin as Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial. Journal of Clinical Oncology, 27, 3109-3116.

[29]   Postma, T.J., Heimans, J.J., Muller, M.J., Ossenkoppele, G.J., Vermorken, J.B. and Aaronson, N.K. (1998) Pitfalls in Grading Severity of Chemotherapy-Induced Peripheral Neuropathy. Annals of Oncology, 9, 739-744.

[30]   Ramfelt, E., Severinsson, E. and Lützén, K. (2002) Attempting to Find Meaning in Illness to Achieve Emotional Coherence: The Experiences of Patients with Colorectal Cancer. Cancer Nursing, 25, 141-149.

[31]   Simpson, M.F. and Whyte, F. (2006) Patients’ Experiences of Completing Treatment for Colorectal Cancer in a Scottish District General Hospital. European Journal of Cancer Care, 15, 172-182.

[32]   Köppler, H., Heymanns, J., Thomalla, J., Kleboth, K. and Weide, R. (2010) The Impact of New Treatment Options for Advanced Colorectal Cancer on Routine Care: Results of a Retrospective Analysis of 206 Consecutive Patients Treated in a Community-Based Oncology Group Practice in Germany. European Journal of Cancer Care, 19, 795-802.

[33]   Attal, N., Bouhassira, D., Gautron, M., Vaillant, J.N., Mitry, E., Lepère, C., Rougier, P. and Guirimand, F. (2009) Thermal Hyperalgesia as a Marker of Oxaliplatin Neurotoxicity: A Prospective Quantified Sensory Assessment Study. Pain, 144, 245-252.

[34]   Börjeson, S., Starkhammar, H. and Berterö, C. (2011) Common Symptoms Experienced among Patients with Colorectal Cancer, and Barriers to Reporting Symptoms or Distress: The Staff Perspective. Austral-Asian Journal of Cancer, 10, 11-20.

[35]   Börjesson, S., Starkhammar, H. and Berterö, C. (2012) Common Symptoms Experienced among Patients with Colorectal Cancer: A Qualitative Part of Mixed Method Design. The Open Nursing Journal, 6, 100-107.